> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Eloctate
- URL: https://www.fdaweb.com/review-period-set-for-eloctate/
- Published: 2016-06-08T12:00:00.000Z
- Updated: 2026-09-14T21:08:21.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135878

*Federal Register* Notice: FDA has determined the regulatory review period for Biogen Idec Hemophilia Inc.’s Eloctate is 1,695 days for extending patents which claim the human biological product. Eloctate is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for controlling and preventing bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-06-08/pdf/2016-13521.pdf?ref=fdaweb.com)